Speaker Profile
M.D., Ph.D., Professor of Medicine (Oncology); C.M.A, Stanford
Biography
Ash A. Alizadeh, MD, PhD is the Moghadam Family Professor of Medicine at Stanford University and a practicing hematooncologist and physician-scientist in the Division of Oncology, leading the Cancer Genomics program for the Stanford Cancer Institute. His research focuses on the development of data-driven approaches to better understand cancer biology, improve diagnostics, and personalize therapies. Dr. Alizadeh is a recognized leader in computational methods for cancer biology and oncology translational research, contributing extensively to the advancement of precision medicine. His group has contributed to the development of several commonly used liquid biopsy techniques for cancer detection and monitoring (including CAPP-Seq, PhasED-Seq, RARE-Seq, EPIC-Seq), as well as methods for tumor immune profiling (including CIBERSORT and EcoTyper).
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Emre Baser, AstraZeneca
PMWC Award Ceremony
• Max Diehn, Stanford (Pioneer)
• Sarah-Jane Dawson, Peter MacCallum Cancer Centre / University of Melbourne (Luminary)
Featured Speakers
• Max Diehn, Stanford
• Sarah-Jane Dawson, University of Melbourne
• Phil Febbo, Veracyte
• Ash Alizadeh, Stanford
• Adrian Lee, University of Pittsburgh
• Emre Baser, AstraZeneca
• Keith Flaherty, Mass General
• Thomas Powles, Barts Cancer Institute
Early-Stage Cancer: Can MRD Decide Who Needs More Treatment?
When ctDNA should change escalation, de-escalation, and surveillance.
Advanced Cancer Monitoring
Detecting response, resistance, and relapse early enough to switch therapy.
From Blood to Drug
Liquid biopsy for therapy selection and matching patients to the right intervention.
Integrating Tissue, Liquid & Imaging Biomarkers
How multimodal monitoring should work in real oncology care.
MRD as a Surrogate Endpoint
The promise and hazards of using MRD to accelerate drug approval.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
